Evidence map›Paper›PMID 30277116›Full record

ArticleLeukemia & lymphoma2019

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Margaret Nieborowska-Skorska, Silvia Maifrede, Min Ye, Monika Toma, Elizabeth Hewlett, John Gordon, Bac Viet Le, Tomasz Sliwinski, Huaqing Zhao, Katarzyna Piwocka and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. NCellular and molecular life sciences : CMLS · 2024
    Review
  2. Article
  3. Article
  4. Allosteric crosstalk in modular proteins: Function fine-tuning and drug design.Computational and structural biotechnology journal · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2020
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Margaret Nieborowska-Skorskaa Department of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Silvia Maifredea Department of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Min Yeb Temple University School of Pharmacy, Moulder Center for Drug Discovery Research , Philadelphia , PA , USA.
Monika Tomaa Department of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Elizabeth Hewlettb Temple University School of Pharmacy, Moulder Center for Drug Discovery Research , Philadelphia , PA , USA.
John Gordonb Temple University School of Pharmacy, Moulder Center for Drug Discovery Research , Philadelphia , PA , USA.
Bac Viet Lea Department of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Tomasz Sliwinskic Laboratory of Medical Genetics Faculty of Biology and Environmental Protection , University of Lodz , Lodz , Poland.
Huaqing Zhaoe Department of Clinical Sciences Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Katarzyna Piwockad Laboratory of Cytometry , Nencki Institute of Experimental Biology , Warsaw , Poland.
Peter Valentf Department of Internal Medicine I Division of Hematology & Hemostaseology and Ludwig-Boltzmann Cluster Oncology , Medical University of Vienna , Austria , Vienna.
Alexei V Tuling Department of Biomedical Sciences School of Medicine and Health Sciences , University of North Dakota , Grand Forks , ND , USA.
Wayne Childersb Temple University School of Pharmacy, Moulder Center for Drug Discovery Research , Philadelphia , PA , USA.
Tomasz Skorskia Department of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine , Temple University , Philadelphia , PA , USA.
Temple University · USUniversity of Łódź · PLInstytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLLudwig Boltzmann Cluster for Cardiovascular Research · ATUniversity of North Dakota · US

Funding

Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALLR01CA186238 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2014 to 2024
$4.5M
PARP-1-dependent transcription in progression and maintenance of renal cell carcinomaR03CA212566 · NCI · UNIVERSITY OF NORTH DAKOTA · PI TULIN, ALEXEI V · 2017 to 2018
$161k
NCI NIH HHS R01 CA186238NCI NIH HHS R03 CA212566
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRCA1 ProteinCell Line, TumorCell SurvivalDrug SynergismHumansLeukemiaPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsSynthetic Lethal MutationsBRCA1 ProteinBRCA1 protein, humanolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID30277116
PMCPMC6445778
OpenAlexW2895415879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.